Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.K. May Retain Value-Based Pricing, Even If Health Care Bill Fails

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.K.’s Health and Social Care Bill is struggling in parliament, but even if it falls, the government’s plans for value-based drug pricing may survive.

You may also be interested in...



Value-Based Pricing Could Boost Global Applicability Of NICE Appraisals

Value-based pricing will start in the U.K. in January 2014 for newly launched products, with prices taking into account innovation and societal benefit as well as NICE's usual clinical and cost-effectiveness analysis, U.K. Health Secretary Andrew Lansley tells NICE's annual conference.

European Regulatory Round-Up: EMA And The UK Heed The Calls Of Industry; France Is Otherwise Occupied

The European Medicines Agency follows through on its transparency initiative with comprehensive list of products under review and also reduces pharmacovigilence data reporting requirements.

EU Transparency Directive Revisions May Accelerate Access To New Medicines, But IP Issues Set To Cause A Storm

Proposed revisions to the EU Transparency Directive could drive faster access to medicines. But innovative product sponsors say IP rules will damage their business.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS073826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel